EP3615072A1 - Procédé de diagnostic - Google Patents

Procédé de diagnostic

Info

Publication number
EP3615072A1
EP3615072A1 EP18746103.3A EP18746103A EP3615072A1 EP 3615072 A1 EP3615072 A1 EP 3615072A1 EP 18746103 A EP18746103 A EP 18746103A EP 3615072 A1 EP3615072 A1 EP 3615072A1
Authority
EP
European Patent Office
Prior art keywords
binding molecule
subset
cells
autonomously
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18746103.3A
Other languages
German (de)
English (en)
Inventor
Ulrich Birsner
Hassan Jumaa
Holger Klapproth
Marc A. Kessemeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AVA Lifescience GmbH
Original Assignee
AVA Lifescience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVA Lifescience GmbH filed Critical AVA Lifescience GmbH
Publication of EP3615072A1 publication Critical patent/EP3615072A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Definitions

  • the present invention relates to the field of production, identification and selection of antibodies or fragments thereof, as well as their use in the diagnosis of cancers, in particular malignant B-cell neoplasms.
  • Malignant B-cell neoplasms are commonly referred to as malignant diseases of the hematopoietic or lymphatic system. They include diseases such as leukemia and count in a broader sense to the cancers.
  • Leukemias are characterized by a greatly increased production of dysfunctional white blood cell precursor cells, which are also called leukemia cells. These cells spread in the bone marrow, displace there the usual blood formation and accumulate as a rule "also greatly increased in the peripheral blood. They can infiltrate the liver, spleen, lymph nodes and other organs, thereby impairing their function.
  • the disruption of blood formation results in a decrease in normal blood components, which may cause anemia due to lack of oxygen-carrying red blood cells, lack of hemostatic platelets, and a lack of mature, functional white blood cells.
  • Acute leukemias are life-threatening diseases that, if left untreated, can lead to death within a few weeks to months.
  • Chronic leukemias usually run over several years and are often symptom poor in the initial stage.
  • AML acute myeloid leukemia
  • CML chronic myeloid leukemia
  • ALL acute lymphoblastic leukemia
  • CLL chronic lymphocytic leukemia
  • leukemias are treated as part of chemotherapy.
  • Newer forms of therapy are increasingly relying on the use of monoclonal antibodies such.
  • GA101 bisnutuzumab
  • rituximab and ofatumumab acts as a CD20 antibody and is used to treat chronic lymphocytic leukemia (CLL).
  • CLL chronic lymphocytic leukemia
  • Other malignant diseases of the hematopoietic or lymphatic system malignant B-cell neoplasms
  • lymphomas such as lymphoma.
  • Hodgkin's lymphoma and B-cell variants of non-Hodgkin's lymphoma are malignant diseases of the hematopoietic or lymphatic system.
  • antibodies are generated against receptors, then usually.
  • these hybridoma cells produce antibodies that are then tested in cell systems by ELISA or expressed receptors, using established cell lines because they are the only ones that are easily cultivated
  • Antibodies can be generated that bind relatively specifically to a specific receptor type (eg, anti-IgGl, anti-IgE), but often cross-react with other receptors or other epitopes.
  • BCR antibodies For a diagnostic application of BCR antibodies, it is usually not sufficient to use only one antibody against the BCR in general, since such a broadband use can lead to false positive results. Rather, it would be desirable to provide an antibody that selectively binds to a receptor that has (pathophysiological) activation, particularly autonomous activation. Such an antibody is not known in the art and a Process for its preparation or production by selection does not exist.
  • the object of the present invention is therefore to provide alternative concepts and means such as in particular alternative antibodies for diagnostic use, which overcome the existing problems of the prior art.
  • neoplasia generally refers to a regeneration of body tissue, which is a malignant or malignant manifestation of malignant neoplasia, malignant B-cell neoplasia thus being a malignant and uncontrolled neoplasm of B cells, these being Conceptuality affects all B-cell associated cancers such as leukemias and B-cell lymphomas alike.
  • biological binding molecules herein are meant, for example, but not limited to, antibodies including fusion proteins
  • an antibody is selected from the group consisting of an IgG antibody, an IgM antibody, a humanized IgG antibody, and a human
  • a binding molecule may also be provided in the form of a functional fragment of the entire antibody, eg a Fab fragment
  • a binding molecule may also comprise further regions or additional entities, the use of which in the context of diagnostic These may be fluorescence dyes (eg: FITC, R-phycoerythrin (R-PE), allophycocyanin (APC)) or biotin as well as other substances known to the person skilled in the art using flow cytometry.Furthermore, a binding molecule may be immunohistochemized Mixer method also together with substrate-converting enzymes (e.g. HRP). Furthermore, fusion proteins can also be provided for diagnostic purposes in which for detection
  • B-cell receptor or B-cell receptor complex BCR
  • BCR B-cell receptor complex
  • the role of the B-cell receptor or B-cell receptor complex (BCR) on the surface of a B-cell is to recognize and bind pathogens, so it can be regarded as a membrane-bound antibody. This binding leads to a conformational change of the BCR, which triggers a signal cascade that ultimately leads to activation of the B cell.
  • the BCR is formed in great variety in maturing B cells. The development of B cells occurs in humans and in some other mammals in the bone marrow or fetal liver. The signals necessary for the development program are obtained from the developing lymphocytes of so-called stromal cells.
  • B-cell development the formation of a functioning B-cell receptor (the membrane-bound form of the 'antibody') is of crucial importance. Only with this antigen receptor are mature B cells later able to recognize foreign antigens and bind to hostile structures through the formation of corresponding antibodies.
  • the antigen specificity of the receptor is determined by the linkage of certain gene segments. The segments are called V, D and J segments, which is why the process is called V (D) J recombination. These segments, which form the antigen-binding part of the B-cell receptor, rearranged.
  • the entire receptor consists of two identical light protein chains and two identical heavy protein chains, with the heavy and the light chains each linked together via disulfide bridges.
  • VDJ recombination first the V, D and J segments of the heavy chain of the B cell receptor are linked, followed by the V and J segments of the light receptor chain. Only when the genes are successfully rearranged, which is referred to as productive gene rearrangement, the cell can go into the next development step.
  • BCR Since the process of generating such a BCR is based on a random assembly of gene segments, it may happen that the newly created BCR recognizes unwanted endogenous structures and thus becomes “permanently activated.” To prevent the emergence of such a "permanently active or activated" BCR There are various body protection mechanisms. However, if these are overcome due to a pathological change in the developing B-cell, it may develop into a malignant or even autoimmune manifesting disease.
  • an “autonomously active” or “autonomously activated” BCR is a special type of permanently active BCR. While conventional activation proceeds from an external antigen (see above), the autonomously active BCR results from its interaction with membrane structures on the surface of the same cell. For the clinical picture of CLL, an autonomous activation-triggering interaction between BCRs could be shown, which were located adjacent to each other on the surface of the same cell (M. Dmixen-von Minden et al., Nature 2012). Another example of an autonomously active BCR is the pre-BCR, which is expressed during the development of a B cell as a development check. In addition to the interaction of neighboring receptors (BCR: BCR), an interaction between the receptor and a membrane protein (BCR: membrane protein) can lead to an autonomously active or activated BCR.
  • BCR neighboring receptors
  • BCR membrane protein
  • the solution according to the invention of these problems is based on the surprising finding that are located on tumor cells of patents with CLL B-cell receptors that are autonomously activated or autonomously activated, and that these autonomously active or activated receptors by the presence of common epitopes that in corresponding Receptors from healthy cells of the same patient can not be detected, Marked are. Due to the presence of autonomously active B cell receptors, which are characterized by the occurrence of the abovementioned epitopes, these cells can thus be specifically recognized by an antibody and, if appropriate, treated, so that healthy B cells without this characteristic are not affected as a result which makes the treatment much more specific and with less undesirable side effects.
  • modified receptor regions can not be prepared and selected by standard methods. Only after the experimental conditions were adapted in such a way that genetically modified cells whose modified B cell receptors were in a native and activated state were used in binding studies were it possible to obtain suitable antibodies with the desired and required specificity. In other words, it is of essential importance for the solutions proposed according to the invention that the cells used in binding studies for the selection of suitable diagnostic antibodies present their modified regions (epitopes) in largely native and activated form. It turned out that so-called pro- / pre-B cells are particularly suitable because of their physiological constitution.
  • the present invention provides diagnostic methods using biological binding molecules in the form of antibodies or functional fragments thereof and a method for producing (identifying and selecting) such binding molecules which selectively binds to the modified epitopes of autonomously active membrane-bound immunoglobulins of B-molecules. Binding cell neoplasia.
  • the biological binding proteins selectively bind to such autonomously active B cell receptors on B cells which occur in immunological (eg autoimmune) diseases and are causally related to them (eg allergies, ulcerative colitis, diabetes mellitus Type 1, multiple sclerosis, psoriasis, rheumatic fever, rheumatoid arthritis, celiac disease).
  • immunological eg autoimmune
  • diseases eg allergies, ulcerative colitis, diabetes mellitus Type 1, multiple sclerosis, psoriasis, rheumatic fever, rheumatoid arthritis, celiac disease.
  • each individual B-cell progenitor generates its own and almost unique B-cell receptor (BCR) through the rearrangement of individual gene segments.
  • BCR B-cell receptor
  • the area of subset 2 relevant for the autonomously active functionality of the receptor is characterized by the amino acid sequences KLTVLRQPKA (SEQ ID NO. 1 ⁇ and VAPGKTAR (SEQ ID NO. 2) of the light chain, while that relevant for the autonomously active functionality of the receptor
  • the sequence of subset 4 is defined by the amino acid sequences PTIRRYYYYG (SEQ ID NO: 3) and NHKPSNTKV (SEQ ID NO: 4) of the variable part of the heavy chain
  • the sequences used for generating the murine antibodies in the immunization for the subsets 2 and 4 are given in SEQ ID Nos.
  • SEQ ID NO: 17 contains another target sequence or epitope Specified specificity for the variable part of the heavy chain of a BCR of the subset 4.
  • OSs 3 and 4 represent the sequence according to SEQ ID NO.
  • the methods used until this finding included not only standard methods such as ELISA and SPR, but also intracellular expression in fibroblasts with an intracellular FACS staining as binding control.
  • the binding molecule proposed according to the invention selectively binds to autonomously active or autonomously activated B cell receptors, which are characterized by the presence of structural domains or epitopes (target sequences) and are responsible for the autonomously active or activated state of B cell receptors.
  • the selective binding behavior of the binding molecule proposed according to the invention for diagnostic use means that it does not bind to receptors or other membrane structures of B cells that have no structural domain or epitope that are responsible for the autonomously active or activated state of B cells.
  • the binding molecule proposed according to the invention does not bind selectively to target sequences of the B cell receptor which are not characteristic for the subset 2 or the subset 4, and in particular not to a B cell receptor which does not contain any of the sequences SEQ ID NOS. 1, 2, 3 and / or 4.
  • pro- / pre-B cells derived from Triple Knockout (TKO) mice is particularly well-suited to these receptors, despite the difficult handling and costly recovery be expressed and used in a test system for the identification of these receptors.
  • the stage of pro- / pre-B cells is naturally designed to carry out the maturation and selection of BCRs, and the cells of this stage are particularly suitable because of their enzyme endowment (chaperones, etc.), even for "difficult" BCR components fold in and on your surface in sufficient physiologically native form.
  • the deletions (knockouts) described below prevent a change in the desired BCR from taking place by recombination or the use of the surrogates light chain ("surrogate light chain").
  • Chromatography which is well known to those skilled in the art, care being taken not to denature the antibodies and to detect possible foreign substances such as e.g. To quantitatively remove proteins, pyrogens and toxins.
  • the desired antibodies are expressed in systems in which the antibody undergoes glycosylation, in particular human glycosylation.
  • Such systems are well known to those skilled in the art and include the use of insect cells (S2 cells), mammalian cells (CHO cells), and, most preferably, human cells such as HEK293T type cells.
  • the sufficiently purified antibody may in itself be therapeutically effective, provided that it has an isotype which elicits a specific immune response, e.g. an IgG subtype that leads to an immune response against the tumor via Fc receptors.
  • the antibody can also be present as a fragment.
  • the fragment to be used is for diagnostic use by coupling to e.g. modified a fluorescent dye, biotin, and / or to an enzymatic subunit in the usual way.
  • the antibody is preferably used in standardized methods such as in a
  • the antibodies, biological binding molecules or functional fragments thereof proposed for diagnostic purposes have a murine backbone.
  • a detection in the flow cytometer is preferably carried out by means of secondary antibodies, or alternatively preferred by means bound directly to the antibodies, biological binding molecules or functional fragments thereof
  • a stabilizing salt buffer e.g. a phosphate buffered saline (PBS), as known to those skilled in the art.
  • PBS phosphate buffered saline
  • a suitable drying form is e.g. Freeze-drying or lyophilization.
  • the production and identification of antibodies that bind selectively to the modified B cell receptors has been characterized by major and unforeseen problems.
  • the generation of the hybridomas was carried out by standard methods.
  • the supernatant from the hybridoma groups was pooled and tested for positive binding events by ELISA (soluble B cell receptors on the ELISA plate). Positive pools were isolated and the individual clones tested. Surprisingly, no positive clones were identified in the ELISA.
  • the positive ELISA signals of the Poole subsequently turned out to be unspecific bindings.
  • the BCR light chain has now been expressed in fibroblasts. This should ensure the correct folding of the protein bearing the motif (epitope) responsible for the autonomic signal. With these cells were intracellular FACS analyzes performed. No positive clone (antibody) could be identified.
  • RAMOS cells human Burkitt lymphoma cell line
  • CRISPR CRISPR
  • CLL receptor CMV vectors
  • pre-BCR Since the pre-BCR is autonomous, this would be proof of an autonomously active receptor. Since a new BCR is cloned into the cell, a pre-BCR is undesirable since it appears on the surface with the desired heavy chain (HC) in conjunction with the undesirable surrogate light chain and the
  • the knockout of SLP65 an adapter protein of central importance in the BCR signaling pathway, prevents activation of the TKO cell by a possibly reconstructed BCR.
  • the combination of the knockouts of RAG2 or RAG1 and lambda5 leads to a blockade in the transition from the pro-B cell stage to the pre-B cell stage, which is classically characterized by the onset rearrangement of the VDJ heavy chain (HC) segments is. Therefore, they are pro- / pre-B cells.
  • the knockout of RAG2 or RAG1 and lambda5 is sufficient. By reconstitution with the inducible SLP65, the activity of the BCR can be measured.
  • the method of choice here is the measurement of Ca flux after induction of the SLP65 by means of FACS analysis and the use of a Ca 2+ -dependent dye such as Indo-1.
  • the first two knockouts ensured that only the "BCR of interest” was expressed on the surface, and the use of an inducible SLP-65, with which the cells were reconstituted, could characterize the function of the expressed BCRs and thus autonomously active state of the BCRs on the surface prior to selection can be verified.With these cells as the "target”, FACS was now able to identify an antibody that was linked to the modified Area, by which the autonomous activation of the BCR is justified and characterized, specifically binds. And this, although binding to the same type of receptor in RAMOS cells was unsuccessful!
  • the cells which carried the "BCR of interest” on the surface were first incubated with the pooled supernatants, and after a few washing steps, the bound antibodies were detected by means of secondary antibodies.TKO cells (TKOs) were used for a specific selection different versions of the "BCR of interest” expressed.
  • the selection matrix shown in FIG. 1 is exemplary for the selection of a CLL subset 2 BCR and was used to identify and select positive clones.
  • the supernatants of the hybridomas were pooled and measured. The groups that showed binding were singulated and the supernatants of the respective hybridomas tested for binding.
  • mice which have a respective knockout for the genes Lambda5, RAG2 and SLP-65 (Dlicken von Minden et al., 2012, Nature 489, p309-313).
  • the preparation of such mice is known in the art and belongs to the prior art.
  • the mice were extracted after their killing the bone marrow of the femurs.
  • the cells thus obtained were then cultured under conditions favoring the survival of pro- / pre-B cells (37 ° C, 7.5% CO2, Iscoves medium, 10% FCS, P / S, murine IL7).
  • a FACS sorting was performed as a control, the pro / pre-B cells were sorted and then returned to culture.
  • the markers used for this purpose are known to the person skilled in the art.
  • the corresponding sequences coding for the heavy (HC) and light (LC) chains were synthesized and then each cloned into a CMV promoter-containing expression vectors. These were incorporated by lipofection into the packaging cell line (Phoenix cell line). After a 36 hour incubation, virus supernatant was removed and used for spinfection of TKO cells. Both the work for the recovery of the supernatants and the spinfection of the TKO are widely known methods and known to the skilled person.
  • subset-2 B cell receptors were taken from the corresponding literature (see above).
  • Exemplary CLL subset 2 VH and complete LC DNA segments were synthesized by a contract manufacturer in a standard procedure. These were then fused with a murine IgGl constant segment by PCR and transformed into a CMV Vector cloned. The sequence of the final vector was confirmed by Sanger sequencing.
  • CLL subsets 2 IgG1 For expression of CLL subsets 2 IgG1, a human cellular expression system based on HEK293T cells was used. For transfection, a polyethyleneimine (PEI) based protocol was used. After several passages, the supernatant was pooled and the medium contained in the pooled cell supernatant was purified by means of Protein G columns. The purity and quality of the soluble Subset-2 IgGl was determined by Western blot.
  • PEI polyethyleneimine
  • the mRNA was isolated from the individual hybridoma clones, from which cDNA was generated and amplified by means of anchor PCR (Rapid Expression Cloning of human immunoglobulin Fab fragments for the analysis of antigenic specificity of B cell lymphomas and anti-idiotype lymphoma vaccination; Osterroth F, alkane 0, Mackensen A, Lindemann A, fish P, Skerra A, Veelken H., J Immunol Methods 1999 Oct 29; 229 (1-2): 141-53).
  • the heavy chain partial sequences corresponding to CDR1, CDR2 and CDR3 according to SEQ ID NO. 9 are in SEQ ID NOS. 11 to 13, while corresponding to CDRl, CDR2 and CDR3 partial sequences of the light chain according to SEQ ID NO. 10 in the SEQ ID NOS. 14 to 16 are shown.
  • CLL Subset 4 LC (SEQ ID NO: 8):
  • a small amount of peripheral blood was withdrawn from a patient.
  • 100 ⁇ of blood was transferred to a reaction vessel and made up with 2 ml of PBS-BSA buffer solution.
  • the sample was centrifuged in an Eppendorf 5804 centrifuge at 1500 rpm for a period of five minutes. The supernatant was discarded and the sediment was well mixed.
  • the antibody was added. The following surface parameters were stained: 1) CD19-FITC, 2) CD5-PE, and 3) the CLL SubSet-2 Specific Antibody (APC) before incubating for 15 minutes at room temperature in the dark. Thereafter, lysis was initiated and the erythrocytes were lysed.
  • APC CLL SubSet-2 Specific Antibody
  • the lymphocyte population was selected and labeled in the FSC / SSC blot. For this selection, it was then focused on the CD19-positive B cells and after binding of the Subset-2 specific antibody analyzed.
  • Figure 2 shows an example of such an analysis using the example of the use of the subset-2-specific antibody.
  • the CD19 positive B cells were selected for further analysis (left panel). These were then examined for binding of the specific antibody (right panel).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le domaine de la production, l'identification et la sélection de molécules de liaison biologiques, telles que des anticorps ou des fragments de ces derniers, ainsi que des procédés de diagnostic les faisant intervenir dans le cadre du diagnostic de maladies cancéreuses comme des néoplasies de lymphocytes B malins. Les molécules de liaison sont en mesure de se lier sélectivement à des récepteurs actifs de manière autonome ou activés de manière autonome, les récepteurs de lymphocytes B actifs de manière autonome ou activés de manière autonome sont caractérisés par la présence de domaines structurels, auxquels la molécule de liaison se lie sélectivement et qui sont la cause de l'état actif de manière autonome ou activé de manière autonome des récepteurs de lymphocytes B.
EP18746103.3A 2017-07-07 2018-07-05 Procédé de diagnostic Pending EP3615072A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17001167 2017-07-07
EP17001166 2017-07-07
EP18162666.4A EP3424527A1 (fr) 2017-07-07 2018-03-19 Proces diagnostique
PCT/EP2018/068316 WO2019008128A1 (fr) 2017-07-07 2018-07-05 Procédé de diagnostic

Publications (1)

Publication Number Publication Date
EP3615072A1 true EP3615072A1 (fr) 2020-03-04

Family

ID=64500047

Family Applications (4)

Application Number Title Priority Date Filing Date
EP18162672.2A Withdrawn EP3424528A1 (fr) 2017-07-07 2018-03-19 Molécules de liaison biologiques
EP18162666.4A Withdrawn EP3424527A1 (fr) 2017-07-07 2018-03-19 Proces diagnostique
EP18746104.1A Pending EP3615073A1 (fr) 2017-07-07 2018-07-05 Molécules de liaison biologiques
EP18746103.3A Pending EP3615072A1 (fr) 2017-07-07 2018-07-05 Procédé de diagnostic

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP18162672.2A Withdrawn EP3424528A1 (fr) 2017-07-07 2018-03-19 Molécules de liaison biologiques
EP18162666.4A Withdrawn EP3424527A1 (fr) 2017-07-07 2018-03-19 Proces diagnostique
EP18746104.1A Pending EP3615073A1 (fr) 2017-07-07 2018-07-05 Molécules de liaison biologiques

Country Status (5)

Country Link
US (2) US11634487B2 (fr)
EP (4) EP3424528A1 (fr)
JP (2) JP7239575B2 (fr)
CA (1) CA3070848A1 (fr)
WO (2) WO2019008129A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424528A1 (fr) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Molécules de liaison biologiques
WO2020221463A1 (fr) * 2019-05-02 2020-11-05 Ava Lifescience Gmbh Procédé de sélection d'une molécule biologique de liaison
EP3733709A1 (fr) * 2019-05-02 2020-11-04 AVA Lifescience Molécules de liaison biologiques
US12698325B2 (en) * 2019-05-02 2026-08-04 Ava Lifescience Gmbh Biological binding molecules
EP4387990A4 (fr) * 2021-08-18 2025-07-30 Univ Pennsylvania Compositions et méthodes pour des récepteurs antigéniques chimériques spécifiques des récepteurs de lymphocytes b
WO2023152204A1 (fr) 2022-02-10 2023-08-17 Ava Lifescience Gmbh Anticorps ciblant le récepteur des lymphocytes b de la leucémie lymphoïde chronique (llc) destinés à être utilisés dans le traitement de llc
EP4227321A1 (fr) * 2022-02-10 2023-08-16 AVA Lifescience GmbH Anticorps contre le recepteur des cellules b de la leucemie lymphoide chronique (llc) utilisées dans le traitement de llc
CA3262006A1 (fr) * 2022-07-25 2024-02-01 Sinabiosolution Gmbh Récepteurs antigéniques chimériques humanisés ciblant le récepteur de lymphocytes b de la leucémie lymphoïde chronique et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
RU2691698C2 (ru) 2012-02-24 2019-06-17 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Антитела против sez6 и способы их применения
WO2014179714A1 (fr) * 2013-05-03 2014-11-06 The Board Of Regents Of The University Of Texas System Génération de vaccins peptoïdes
JP2016531915A (ja) * 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
EP3424528A1 (fr) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Molécules de liaison biologiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Abstract LB-012: Autonomous, antigen-independent B-cell receptor signalling as a novel pathogenetic mechanism in non-GCB DLBCL | Cancer Research", 20 July 2016 (2016-07-20), XP055501506, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/76/14_Supplement/LB-012> [retrieved on 20180822] *
ANONYMOUS: "B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia - Binder - 2011 - Cancer - Wiley Online Library", 1 May 2011 (2011-05-01), XP055501580, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.25755> [retrieved on 20180823] *
JUMAA HASSAN: "Die Rolle der Autoreaktivität für die B-Zell-Entwicklung | Max-Planck-Gesellschaft", 1 January 2012 (2012-01-01), XP055481469, Retrieved from the Internet <URL:https://www.mpg.de/4686347/Autoreaktivitaet_B-Zell-Entwicklung> [retrieved on 20180606] *
ROMANA RUISSMOUS: "EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells-A New Option for the Treatment of B-CLL", 10 October 2011 (2011-10-10), XP055481516, Retrieved from the Internet <URL:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0025294> [retrieved on 20180606] *
See also references of WO2019008128A1 *

Also Published As

Publication number Publication date
JP2020526590A (ja) 2020-08-31
US11591391B2 (en) 2023-02-28
WO2019008128A1 (fr) 2019-01-10
EP3615073A1 (fr) 2020-03-04
CA3070847A1 (fr) 2019-01-10
CA3070848A1 (fr) 2019-01-10
EP3424528A1 (fr) 2019-01-09
US11634487B2 (en) 2023-04-25
JP2020527727A (ja) 2020-09-10
WO2019008129A1 (fr) 2019-01-10
US20200209246A1 (en) 2020-07-02
US20200199225A1 (en) 2020-06-25
EP3424527A1 (fr) 2019-01-09
JP7239575B2 (ja) 2023-03-14
JP7271532B2 (ja) 2023-05-11

Similar Documents

Publication Publication Date Title
WO2019008128A1 (fr) Procédé de diagnostic
DE69128253T2 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
DE60226036T9 (de) ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
DE69330523T3 (de) Immunoglobuline ohne leichte ketten
AT411997B (de) Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
DE69730209T2 (de) Multivalentes und multispezifisches Antigenbindungsprotein
DE69126607T2 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
EP0531300B1 (fr) Variantes de proteines superficielles cd44, sequences d&#39;adn les codant, anticorps contre ces proteines, ainsi que leur utilisation dans le diagnostic et la therapie
DE60129278T2 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
DE69837337T2 (de) Herstellung von proteinen in eiern
EP3899536B1 (fr) Procédé de sélection de molécules de liaison biologiques
DE60224200T2 (de) Assayverfahren für alzheimer-krankheit
DE69333039T2 (de) Monoklonaler antikörper gegen ein humanes mdr1-gen produkt, das eine resistenz gegen verschiedene medikamente erzeugt und seine verwendung
DE69634092T2 (de) Herstellung von antikörpern
DE69221845T2 (de) Monoklonale Antikörper gegen humanes IgE
WO2020221466A1 (fr) Molécules de liaison biologiques
EP3543697B1 (fr) Procédé de sélection de molécules de liaison biologiques
EP0537489A1 (fr) Anticorps monoclonaux contre des antigènes associés aux tumeurs, procédé de préparation et utilisation
EP3733709A1 (fr) Molécules de liaison biologiques
WO2020221463A1 (fr) Procédé de sélection d&#39;une molécule biologique de liaison
DE69813181T2 (de) Icam-4 und dessen diagnostische verwendungen
EP0115062A2 (fr) Anticorps monoclonaux, réagissant à l&#39;essai d&#39;agglutination directe et spécifiques de l&#39;antigène humain du groupe sanguin D (Rh0) et lignées cellulaires d&#39;hybridomes produisant ces anticorps monoclonaux
DE69133287T2 (de) An tag-72 bindende zusammengesetzte antikörper mit der humanen leichten kette der untergruppe-iv
WO2001049710A2 (fr) Procede pour identifier des substances imitant les epitopes de mammiferes
EP0738282A1 (fr) Nouveaux anticorps chimeres, leur utilisation et leur procede de production

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210819

19A Proceedings stayed before grant

Effective date: 20230512

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVA LIFESCIENCE GMBH